Kornimate/medical-research-clean huggingface dataset:
use of tissue plasminogen activator in the clearance of chronic subdural hematomas

Conditions: Hematoma, Subdural; Fibrinolytic; Hemorrhage

Summary: to determine the utility of tissue plasminogen activator (tpa) in the clearance of chronic subdural hematomas (csdh). intra-catheter tpa will be administered during surgical procedure and allowed to break down blood clot to assist with removal/drainage during twist drill craniostomy procedure.

a chronic subdural hematoma (csdh) is a collection of blood overlying the brain that can be seen, usually in the elderly with even minimal head trauma. these are usually treated by removing the collection of blood. this can be done through a small drill hole in the skull or by larger holes (one or two) the size of a nickel. sometimes a larger piece of skull is removed to be able to remove the csdh. the standard practice at our center is to do these procedures under local anesthesia with a twist drill craniostomy (small drill hole through the skull). in some cases, all the csdh can not be removed the first time, requiring a second procedure or a larger procedure. this study plans to use a type of medication that breaks down the solid blood clot, enabling more of it to drain. this medication (tpa) is already used in other surgeries and is safe to use in humans. our preliminary experience and that of others suggests very low risk at the dosages being used. we hope that using this new drug will decrease the chance of the csdh collecting again and reduce the overall length of your stay in the hospital and reduce the need for further surgery.

Eligibility criteria:
inclusion criteria: 1. adult patients (18 yrs or older) 2. admitted to neurosurgery wing at the hospital 3. symptomatic patients requiring surgical drainage by twist drill craniostomy exclusion criteria: 1. patients at increased risk of bleeding such as patients taking anticoagulation medication that required reversal at time of intervention، or those with coagulopathic disorder. 2. patients on antiplatelets or anticoagulation medications (doacs or warfarin) with appropriate holding period prior to drainage, those who are eventually minimized to a regular bleeding risk compared to the normal population, will be included in the study. 3. patients with subdural empyema. 4. redo twist drill craniostomy for residual csdh within the same admission. 5. drain accidentally removed during nursing care or patient transport before 24 hr interval scan. 6. patients who are not expected to live more than three months.
taste changes in acute otitis media

Conditions: Acute Otitis Media

Summary: detection of taste changes in acute otitis media (aom) patients.

methods: taste assessment will be done using electrogustometer (egm). tongue stimulation will be performed using low currents of up to 100ua. using the protocol as specified in the egm user manual. population: 40 unilateral aom patients, aged 8-40. without chronic otitis media, pregnancy or impaired judgement.

Eligibility criteria:
inclusion criteria: * unilateral aom exclusion criteria: * chronic otitis media * pregnancy * patients with lack of judgment

Keywords: acute otitis media aom electrogustometer egm taste threshold
changes in the immune response and skin reactivity of grass pollen allergic patients treated with alk grass tablets

Conditions: Allergy

Summary: we plan to determine changes in the immune system during the allergic response to grass pollen allergens. we have chosen a particular element of the immune response, the immunoglobulin g4 (igg4) as an indicator. we hypothesize that treatment with grazax will increase serum levels of phleum pratense specific igg4 and ige, as well as reduce the cutaneous sensitivity of the early (ige mediated) and late (cell mediated) allergic response.


Eligibility criteria:
inclusion criteria: * a history of grass pollen allergy * positive skin prick test to grass * positive specific ige to grass exclusion criteria: * treatment with anti-ige

Keywords: rhinitis oral tablets ig g4 grass pollen inmunotherapy
study into treatment of hyperplasia of mammary glands

Conditions: Hyperplasia

Summary: hyperplasia of mammary glands is a complex disease, and there is no consensus or guideline for the treatment of this disease. this study was launched to investigate into the problem that which patients should be diagnosed as hyperplasia of mammary glands and which patients should be treated.

females who meet the inclusion criteria will receive breast ultrasonography, mammography and pathological examinations by core needle biopsy. all participants will receive a follow-up at an 6-month interval for 2 years. during the follow-up period, whether the symptoms relieve will be evaluated.

Eligibility criteria:
inclusion criteria: * reported breast pain or breast lumps. * willing to be kept follow-up. * functions below are maintained in major organs: liver, renal and heart. * written informed consent will be obtained for patients for entering this study. exclusion criteria: * typical breast cancer or fibroadenoma. * classification by breast ultrasonography of mammography is beyond breast imaging - reporting and data system (bi-rads) 4. * oral contraceptive or hormone replacement therapy. * history of breast cancer or other malignancies. * history of pituitary gland disease. * potentially pregnant, pregnant, or breast-feeding.
a study to evaluate the ddi of hsk7653 with metformin

Conditions: Type 2 Diabetes Mellitus

Summary: this is a phase 1, single center, open-label, single arm, drug-drug interaction study of hsk7653 and metformin in healthy subjects.


Eligibility criteria:
inclusion criteria: * age ≥18 and age ≤60 years * bmi ≥18 and bmi ≤ 28 kg/m2 (body mass index) * able to understand the procedures of the study, and provide written informed consent and willing to comply with the study protocol procedures. exclusion criteria: * any finding of the medical examination (physical examination, laboratory examination, 12-ecg, abdominal b-ultrasonography, etc) deviating from normal and of clinical relevance during screening; * fasting blood glucose \<3.9mmol/l or ≥6.1mmol/l; * has a condition affecting the absorption, distribution, metabolism, and excretion of the drug; * has a positive result on screening for serum hepatitis b surface antigen (hbsag), hepatitis c antibody (hcvab), treponema pallidum antibody (tp-ab) or human immunodeficiency virus (hiv); * treatment with an investigational drug within 3 months; * other protocol-defined exclusion criteria.
laparoscopic sleeve gastrectomy short term follow up

Conditions: Morbid Obesity

Summary: laparoscopic sleeve gastrectomy (lsg), also known as longitudinal or vertical gastrectomy. lsg was initially considered a first-stage operation in high-risk patients before bilio-pancreatic diversion or roux-en-y gastric bypass surgery. however, lsg was subsequently found to be effective as a single procedure for treatment of morbid obesity.lsg functions mainly as a restrictive procedure in which about 75 % of the stomach is removed leaving a narrow gastric tube or sleeve. so, it limits the amount of food that can be eaten at one time via inducing early satiety after eating a small amount of food due to early distension of the fashioned gastric sleeve giving a sense of satiety, consequently losing excess body weight by time.sleeve gastrectomy may also cause a decrease in appetite by reducing the amount of ghrelin (hunger hormone) produced by the stomach.

all patients,males and females with age (20-50 years old) with morbid obesity (bmi ≥ 40 kg/m2 or \> 35 kg/m2 associated with co-morbidity) randomly admitted to assiut university hospital-general surgery department. pre-operative: assessment of; bmi (body mass index), fasting blood glucose level (fbg), associated co-morbidities (as hypertensions \& sleep apnea). operative (during operation): all patients undergo lsg by single team work with intra-operative oesophageal bougie 36 french with use of laparoscopic gastro-intestinal anastomosis(gia) stapler. post-operative: patients are discharged from the hospital after they can start oral diet. post-operative evaluation of: 1. complications: 1. early complications: during the first 2 weeks after surgery,which include hemorrhage (intra-luminal or extra-luminal), staple line leak, vomiting and infection (surgical site infection or intra- abdominal abscess formation) 2. late complications: from 2 weeks to 6 months post-operative, which include stricture of the gastric sleeve, gastro-esophageal reflux disease (gerd) and nutritional deficiencies. 2. excess weight loss (ewl) by using bmi follow up of patients at fifteen days, one month, two months, three months and six months after surgery. 3. assessment of blood glucose level during visits. 4. measurement of blood pressure during visits (if there is associated hypertension).

Eligibility criteria:
inclusion criteria: * all patients,males and females with age (20-50 years old) with morbid obesity (bmi ≥ 40 kg/m2 or \> 35 kg/m2 associated with co-morbidity), and are fit for laparoscopic surgery. exclusion criteria: * patients having severe co-morbidity who are not fit for surgery or general anaesthesia. * patients with age below 20 years or above 50 years.
improving knowledge about infertility; an online educational tool

Conditions: Infertility

Summary: the purpose of this study is to determine the effectiveness of an online informational video in improving knowledge about infertility in couples experiencing problems conceiving. a pilot study will be conducted with first and second year medical students.

this study is being conducted to assess how a short, online educational video changes knowledge about fertility and infertility in couples attending an infertility clinic for the first time. participants will complete a questionnaire testing knowledge about infertility and general demographic information (age, gender, previous information sources on infertility, etc.) will be collected. participants will then be directed to a short video on infertility. one week later, participants will return to the site to complete the infertility test questions a second time in order to test memory retention. the focus of both the questionnaire and educational video will be basic reproductive biology, infertility risk factors, etiologies and treatments and fertility myths.

Eligibility criteria:
inclusion criteria: * women between the ages of 18 and 60 years * men between the ages of 18 and 60 years * booking an appointment at the infertility clinic for the first time * access to a computer with internet connection * for pilot study: students must be in first or second year medical school before teaching on infertility exclusion criteria: * previous appointment at the infertility clinic/ previous medical specialist counsel about infertility * completion of the study surveys after their appointment at the infertility clinic

Keywords: infertility education risk factors fertility knowledge fertility myths
exciteosa for treatment of moderate obstructive sleep apnea

Conditions: Sleep Apnea, Obstructive

Summary: the objective of this study is to assess the efficacy of the exciteosa device amongst a sample of patients with moderate osa. the study is a multi-center, prospective, open-label, randomized, parallel-arm trial of exciteosa (administered at two doses) versus no-therapy for six weeks. up to 120 participants will be enrolled, in order to randomized n=62.


Eligibility criteria:
inclusion criteria: * aged \>=18 years; * diagnosed with moderate osa; * smartphone or tablet capable of running the exciteosa app; * fluent in written and spoken english. exclusion criteria: * bmi \>=35 kg/m2; * implanted medical device; * dental braces and/or intraoral metal jewelry; * any condition impacting the tissue of the oral cavity, including but not limited to ulceration or periodontitis; * symptomatic nasal pathology such as septal deviation, nasal polyposis, or chronic rhinosinusitis; * tonsillar hypertrophy (tonsil size grade 3 or greater); * clinically significant facial or oropharyngeal abnormalities such as class 2 malocclusion; * prior oropharyngeal surgery for sleep-disordered breathing; * at-home use of a mandibular advancement device or pap for sleep-disordered breathing within the previous four weeks; * use of any overnight therapy that cannot be withdrawn during study enrollment; * diagnosed with any sleep disorder other than osa; * chronic use of central nervous system depressants; * driver in a sleepiness-related vehicular accident or near-miss within the two years prior to enrolment (self-report); * employed as a commercial driver, pilot, or other occupation that may be impacted by hypersomnolence; * considered by the pi to be at risk of an ae resulting from hypersomnolence; * any periods of non-connectivity (wifi or cellular data) exceeding 48 hours planned to take place, or likely to take place, during enrollment; * current or planned pregnancy; * member of a vulnerable population, including but not limited to prisoners and those lacking consent capacity; * clinically-significant burden of comorbidities (including history of myocardial infarction, cardiac arrhythmia, heart failure, history of stroke, or transient ischemic attack), and/or any other limitation or condition that may impact the patient's ability to complete the study protocol and use the device per the instructions for use (pi discretion); * employee and/or residing household member who is an employee of a company that produces or distributes products designed to diagnose, treat, and/or monitor sleep or sleep-disordered breathing (including the sponsor).
study of food aversion in patients with anorexia nervosa

Conditions: Anorexia Nervosa

Summary: this study uses a meal-challenge protocol to assess if patients with anorexia nervosa show a differential metabolism in response to food in comparison to healthy controls. this study determines how heritable and biochemical factors influence food metabolism in anorexia nervosa in order to develop more effective treatment strategies.

anorexia nervosa is a brain-based disorder that often leads to serious health consequences including death. the ephx2 gene has been identified as a susceptibility gene for anorexia nervosa. this study utilizes a multi-omics biomarker system approach to investigate how genetic factors interact with dietary factors to influence food aversion, psychopathology, and clinical outcome in patients with anorexia nervosa.

Eligibility criteria:
inclusion criteria: * ill an subjects will meet current diagnostic and statistical manual of mental disorders (dsm v) diagnosis of an, body mass index (bmi) between 11 kg/m² and 17.5 kg/m², or bmi \> 17.5 kg/m² with active eating disorder symptoms. * recovered an must meet the following criteria at time of study entry: 1) current or past dsm v diagnosis of an; 2) bmi between 18.5 kg/m2 and 30 kg/m2; 3) having maintained a bmi of \>18.5 for at least one year. * control must be healthy adolescent or woman negative on our screen for an, other axis i psychiatric illnesses, and having maintained a bmi of between 18.5-30 kg/m² since the age of 18. exclusion criteria: * exclusion criteria for an and control subjects include: organic brain syndrome, schizophrenia and schizoaffective disorder, untreated thyroid disease, renal disease, hepatic disease, and the regular use of fish-oil containing supplements within the last three months of the study. all pregnant and lactating individuals will be excluded.

Keywords: psychopathology treatment epoxide hydrolases polyunsaturated fatty acids eicosanoids
safety and efficacy of automatic testing feature in new icds and crt-ds

Conditions: Heart Failure; Ventricular Arrythmias

Summary: this study is a prospective, non-randomized, multi-center clinical trial that will assess the safety and effectiveness of investigational models of the promote™ rf crt-d and current™ rf icd devices. these new icd and crt-d devices have new features that allow the device to periodically check how much energy is needed to pace a patient's heart and to automatically adjust the amount of energy used to pace the heart.

all patients enrolled in the study will have their device tested to determine if the device can automatically measure how much energy is needed to pace the patient's heart. if the test is successful, the patient's device will be programmed to turn that feature on. 3 months after enrollment, the patient will return to the clinic to have their device re-tested using an automatic test method to measure the amount of energy needed to make the patient's heart beat. a manual test method will also be used to measure the amount of energy needed to make the patient's heart beat. the intent of the study is to show the automatic method works just as well as the manual method.

Eligibility criteria:
inclusion criteria: * have an approved indication, as outlined by american heart association/heart rhythm society (aha/hrs) guidelines, for implantation of an icd or crt-d for the treatment of life-threatening ventricular tachyarrhythmia(s) or heart failure, or undergo revision of their icd or crt-d system to replace the pulse generator. * have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluations. exclusion criteria: * have a classification of status 1 for cardiac transplantation or consideration for transplantation over the next 3 months. * have had a recent myocardial infarction, unstable angina or cardiac revascularization (percutaneous transluminal coronary angioplasty (ptca), stent or coronary artery bypass graft(cabg)) within 40 days of enrollment. * have had a recent cerebrovascular accident (cva) or transient ischemic attack (tia) within 3 months of enrollment. * are allergic to dexamethasone sodium phosphate (dsp). * be currently participating in a clinical investigation that includes an active treatment arm. * be pregnant or are planning for pregnancy within 6 months following enrollment. * have a life expectancy of less than 6 months. * be less than 18 years of age.

Keywords: heart failure cardiac resynchronization therapy autocapture current rf promote rf
a clinical study of herombopag in tumors-associated thrombocytopenia

Conditions: Tumor Therapy-related Thrombocytopenia

Summary: the purpose of this study is to confirm the safety and efficacy of herombopag in tumors-associated thrombocytopenia

cit is one of the most common complications of tumor treatment, which is caused by the inhibition of anticancer chemotherapy drugs on megakaryocytes in bone marrow, resulting in platelet count lower than 100×109/l in peripheral blood, and is a common hematological toxic reaction in clinic. cit leads to an increased risk of bleeding and transfusion, and severe cit can cause intracranial bleeding and death. the use of platelet infusion is limited and ineffective in 25% of patients. rhil-11 increases the incidence of cardiovascular events and rhtpo may produce immunogenicity. currently, tpo-ra is recommended for the treatment of cit by consensus guidelines at home and abroad. the study was designed to explore the safety and efficacy of herombopag in the treatment of tumour-associated thrombocytopenia.

Eligibility criteria:
inclusion criteria: 1. age ≥18, no gender limitation; 2. participants with solid tumors confirmed by histopathological or cytological examination; 3. during the current tumor treatment cycle, the participants whose plt\<50×109/l, and will receive the current tumor treatment regimen for at least 1 cycle; 4. eastern cooperative oncology group (ecog) performance status of 0, 1, or 2. 5. voluntarily participated in the study and signed the informed consent with good compliance. exclusion criteria: 1. suffering from any of the following diseases of the hematopoietic system other than thrombocytopenia caused by tumor therapy, including but not limited to leukemia, primary immune thrombocytopenia, myeloid proliferative disease, multiple myeloma and myelodysplastic syndrome; 2. suffering from thrombocytopenia (not caused by tumor treatment), including but not limited to chronic liver disease, hypersplenism, infection, and bleeding, within 6 months prior to screening; 3. bone marrow invasion or bone marrow metastasis; 4. received radiation therapy to the pelvis, spine and bone field within 3 months prior to screening; or is/is expected to receive radiation therapy. 5. received tpo-ra drugs (such as altrepopal and romistine), or rhtpo or rhil-11 in the current cancer treatment cycle; 6. received platelet transfusion within 3 days prior to randomization; 7. participants with known or expected allergy or intolerance to the active ingredient or excipient of herombopag olamine tablets; 8. pregnant or lactating women; 9. participants who are participating in other clinical trials. 10. other conditions that the investigator determines are not suitable for inclusion in the study.
nutritional intervention in geriatric patients

Conditions: Malnutrition

Summary: this study aims to investigate the effect of a multi-disciplinary nutritional intervention program in geriatric nutritional at risk patients. the study is carried out as randomized controlled trial. the intervention consists of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks).


Eligibility criteria:
inclusion criteria: * age 65 or above * bmi \<20.5 and/or weight loss within the last 3 months and/or a reduced dietary intake in the previous week and/or severely ill exclusion criteria: * terminal illness * active cancer diagnosis * permanently living in a nursing home * not willing or able to give an informed consent.

Keywords: geriatrics nutritional risk multi-disciplinary intervention randomized controlled trial
clinical evaluation of class ii restorations

Conditions: Dental Caries; Dental Caries Class II

Summary: this study aims to evaluate the one-year clinical performance of class ii restorations made with high-filling injectable and condensable universal composite resins. the study included 71 patients and 140 restorations. it used g-aenial universal injectable (gci), g-aenial a'chord (gca), tetric prime (tp), filtek ultimate (fu) composites, and the clearfil se bond adhesive system. restorations were evaluated and scored according to modified usphs criteria at seven days, six months, and one year. chi-square and cochran q tests were used for statistical analysis (p\<0.05).


Eligibility criteria:
inclusion criteria: a patient presenting with; 1. over 18 years of age 2. a normal periodontal status and good general health 3. proximal caries that are similar in size to premolar and molar teeth 4. vital teeth 5. teeth in contact with the opposing tooth and subjected to normal occlusal forces 6. attend follow-up appointments exclusion criteria: 1. poor oral hygiene status 2. those with severe or chronic periodontitis 3. absence of adjacent and antagonist teeth 4. potential behavioral problems (e.g. bruxism) 5. allergy to any product used in the study 6. exposure of the pulp during cavity preparation 7. systemically unhealthy 8. pregnant and lactating women
sticker pad containing essential oil in volunteer with high blood pressure

Conditions: High Blood Pressure

Summary: the aims of the study were to evaluate efficacy and safety of the sticker pads containing lavender and ylang ylang oil in high blood pressure volunteers

high blood pressure volunteers were divided into the sticker group or the placebo group. the volunteers attached the pad to their shirt for 3, 7, 10, and 14 days. blood pressure, pulse rate, adverse reactions, and satisfaction were investigated.

Eligibility criteria:
inclusion criteria: * age more than 18 years * systolic blood pressure of more than 130 mmhg but less than 160 mmhg or diastolic blood pressure more than 80 mmhg but less than 100 mmhg * no hypertensive medicine * no dermatological diseases, immunocompromised diseases, seizures, asthma, or respiratory diseases exclusion criteria: * an unstable condition of other diseases * olfactory problems * pregnancy * lactation